D&B Business Directory
Incyte Corporation
#747 Fortune 1000 Revenue Rank | Website
Overview
Incyte
Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Its portfolio focuses on areas of high unmet medical need and includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products JAKAFI (ruxolitinib), ICLUSIG (ponatinib), PEMAZYRE (pemigatinib) and OPZELURA (ruxolitinib) cream, as well as MINJUVI (tafasitamab) and ...
Read More
MONJUVI (tafasitamab-cxix), which are co-commercialized. In addition, its exclusive licensees sell its OLUMIANT and TABRECTA products.
Read Less
# 747  Fortune 1000 Revenue Rank
Bill Meury   See more contacts
?
?
Modelled

?
Actual
$4.24 billion
Actual
14.76% -94.54% $5,444 DEC
? ?
NASDAQ:INCY
Contacts
Get in Touch with 5 Principals* and 946 Contacts
  • Bill Meury
    Chief Executive Officer
  • Contact 2
    ?
  • Contact 3
    ?
  • Contact 4
    ?
D&B Hoovers Logo

Dynamic search and list-building capabilities

Real-time trigger alerts

Comprehensive company profiles

Valuable research and technology reports

Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$4.24 billion USD
Actual
Stay on top of your Business Credit File
Get full access to view your D&B business credit file now for just $39/month!
View D&B Scores & Ratings